Medical Specialty >> Gynecology
New Study Shakes Up Thinking on Hormone Replacement Therapy
9:00 AM CST.
By Amy NortonHealthDay Reporter Read article
- Breast Cancer Drug Shows Long-Lasting Prevention Power
- Two Drugs Make Inroads Against Aggressive Breast Cancers
- Good Workouts Might Extend a Woman’s Life
- Domestic Abuse Can Leave Legacy of Poor Health
JOURNAL UPDATE
Prenatal, Early-Life Air Pollutant Exposure Tied to Later Allergies
12:00 PM CST. Exposures to candles, cats, environmental tobacco smoke at certain timepoints tied to allergies…- Evidence Supports Use of High-Dose Aspirin for Migraine
- Cost Saving-Related Rx Nonadherence Found for 7 Percent With HIV
- Potentially Nephrotoxic Meds Prescribed to Children With CKD
MONTHLY JOURNAL SUMMARY
November 2019 Briefing - OBGYN & Women’s Health
December 02, 2019. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.
FEATURED ARTICLES
Immunotherapy with Checkpoint Inhibitors in Triple Negative Breast Cancer (TNBC)
Karima Oualla, MD.
Dr. Karima Oualla discusses recent advances on the use of checkpoint inhibitors in the treatment of triple negative breast cancer (TNBC). Dr. Oualla is an International expert in breast cancer and is the primary author of the manuscript entitled "Novel therapeutic strategies in the treatment of triple-negative…
Rucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial
Robert L. Coleman, MD.
Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…
Characterization of patients with ovarian carcinoma who respond to the PARP inhibitor rucaparib
Elizabeth M. Swisher, MD.
Dr. Elizabeth M. Swisher comments on the implications of new data from the ARIEL2 trial, an ongoing Phase 2 trial of the novel PARP inhibitor rucaparib in relapsed, high-grade serous or endometrioid ovarian cancer. The new results offer an important insight into the genetic mechanisms behind tumor sensitivity…
MEDICAL FOCUS
Breast cancer
By Tamer M. Fouad, M.D. Breast cancer is a cancer that starts in the cells of the breast. Worldwide, breast cancer is the second most common type of cancer after lung cancer (11.9%…
DISCUSSION
RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
By namabcAs I understand, this is a great step of development that we can use to save many people from horrible diseases. and i also hope Dr.Lain and your partners…
